Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

Boaz Nachmias; Svetlana Krichevsky; Dvora Filon; Ehud Even-Or; Moshe E. Gatt; Revital Saban; Batia Avni; Sigal Grisariu; Shlomzion Aumann; Vladimir Vainstein

doi:10.1159/000526353

Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

Boaz Nachmias^*, Svetlana Krichevsky, Dvora Filon, Ehud Even-Or, Moshe E. Gatt, Revital Saban, Batia Avni, Sigal Grisariu, Shlomzion Aumann, Vladimir Vainstein

^*Corresponding author for this work

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.

Original language	English
Pages (from-to)	642-649
Number of pages	8
Journal	Acta Haematologica
Volume	145
Issue number	6
DOIs	https://doi.org/10.1159/000526353
State	Published - 1 Nov 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.

Keywords

Acute myeloid leukemia
Minimal residual disease
RUNX1 mutation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000526353

Cite this

@article{c6177925516b48b79e243391023a8b15,

title = "Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia",

abstract = "Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.",

keywords = "Acute myeloid leukemia, Minimal residual disease, RUNX1 mutation",

author = "Boaz Nachmias and Svetlana Krichevsky and Dvora Filon and Ehud Even-Or and Gatt, {Moshe E.} and Revital Saban and Batia Avni and Sigal Grisariu and Shlomzion Aumann and Vladimir Vainstein",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.",

year = "2022",

month = nov,

day = "1",

doi = "10.1159/000526353",

language = "אנגלית",

volume = "145",

pages = "642--649",

journal = "Acta Haematologica",

issn = "0001-5792",

publisher = "S. Karger AG",

number = "6",

}

TY - JOUR

T1 - Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

AU - Nachmias, Boaz

AU - Krichevsky, Svetlana

AU - Filon, Dvora

AU - Even-Or, Ehud

AU - Gatt, Moshe E.

AU - Saban, Revital

AU - Avni, Batia

AU - Grisariu, Sigal

AU - Aumann, Shlomzion

AU - Vainstein, Vladimir

N1 - Publisher Copyright: © 2022 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.

PY - 2022/11/1

Y1 - 2022/11/1

N2 - Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.

AB - Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.

KW - Acute myeloid leukemia

KW - Minimal residual disease

KW - RUNX1 mutation

UR - http://www.scopus.com/inward/record.url?scp=85142939333&partnerID=8YFLogxK

U2 - 10.1159/000526353

DO - 10.1159/000526353

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35933982

AN - SCOPUS:85142939333

SN - 0001-5792

VL - 145

SP - 642

EP - 649

JO - Acta Haematologica

JF - Acta Haematologica

IS - 6

ER -

Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this